Navigation Links
King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control

>

ALTACE should not be taken during pregnancy, as death or injury to an unborn child may result, or if serious side effects related to previous ACE inhibitors have occurred. Prescription ALTACE is not for everyone. ALTACE may cause swelling of the mouth, tongue, or throat, which could cause extremely serious risk and requires immediate medical care. ALTACE may lower blood sugar if taken for diabetes. A physician should be contacted if one experiences symptoms of low blood sugar such as sweating or shakiness. Common side effects include persistent dry cough, dizziness, and light-headedness due to low blood pressure.

For a copy of the ALTACE prescribing information, please visit http://www.altace.com/.

About Hydrochlorothiazide

Hydrochlorothiazide is a thiazide diuretic used in the management of hypertension either alone or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. It is contraindicated in patients with hypersensitivity to hydrochlorothiazide or other sulfonamide-derived drugs. It should be used with caution in patients with renal disease, impaired hepatic function or progressive liver disease, diabetes, gout or lupus erythematosus. Common side effects include dizziness, light-headedness, low blood pressure, dehydration and stomach irritation.

About King Pharmaceuticals

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.

Forward-looking Statements

This release contains forward-looking statements which reflect managem
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

Post Your Comments:
(Date:11/6/2009)...M, N.C., Nov. 6 Oxygen B...day announced that a previously approved reverse s...tart of trading on Monday, Nov. 9, 2009 on a 1-for...Inc. shares will trade under the new symbol OXBT. ...P 20 9, when the split becomes effective. ,, "T...
(Date:11/6/2009)...STOWN, N.J., Nov. 6 Wats...specialty pharmaceutical company, announced today ...cutive officer, will provide an overview and updat...8th Annual Healthcare Conference on Wednesday, Nov...,, This presentation will be webcast live and c...
(Date:11/6/2009)...ESTON, S.C., Nov. 6 T...g in South Carolina and Georgia throughout the wee...elp uninsured and financially-struggling patients ...iption medicines for free or nearly free. With the...nt, the Partnership for Prescription Assistance (P...
Breaking Medicine Technology:Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 2Oxygen Biotherapeutics, Inc. Announces 1:15 Reverse Stock Split to Take Effect Nov. 9, 2009 3Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 2Partnership for Prescription Assistance Prepared to Help Southern Workers Hurt by Recession 3Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 1Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 2Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 3Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes 4918 4New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 1New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 2New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 3New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 4New Large Scale Global Study Provides Additional Information About an Intensified Dose Regimen of PLAVIX 28R 29 in Acute Coronary Syndrome Patients U 4917 5Get Ready for Ragweed 55647 1Get Ready for Ragweed 55647 2
... Italy, April 26 Schering-Plough Corporation,(NYS...ed interim analysis of,an ongoing Phase II study o... protease inhibitor, in 595 treatment-naive patien... were presented at the 43rd Annual,Meeting of the ...ASL). The,ongoing study evaluates boceprevir in 28...
...Large Study Comparing Leading Hepatitis C Therapie...ide Clinical Practice, MILAN, Italy, April 26 Fi...andomized, clinical study comparing the,leading th...day at the 43rd,Annual Meeting of the European Ass...ing important insights that may help guide clinica...
Other Medicine Technology:Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10
(Date:11/8/2009)...UCW Academy of Health holds open house at Victoria...ocus) November 8, 2009 -- UCW Academy of Health in...Columbia’s health care industry to attend th...25, 2009. , ,UCW Academy of Health, which offers ...and social services, designs its programs to meet ...
(Date:11/8/2009)...New book called "Preventing and Healing AIDS ...raldo shows that AIDS is a result of multiple, rep...ed immune system stressor agents, which can be eit...l, emotional. , Oakland,...; 8, 2009, cell biologists, physicians, chemists a...
(Date:11/8/2009)...PRNewswire-USNewswire/ -- Today, the House of Repr...kemper, Smith, Ellsworth and Lipinski amendment to.... 3962). The amendment maintains the current polic...or benefits packages that include abortion. It cla...fordability credits and those who do not, can with...
(Date:11/8/2009)...sage of H.R. 3961 to Secure the Stability of Medic... -- Statement Attributable to: J. James Rohack, M.... (Logo: http://www.newscom.com/cgi-bin/prnh/2008...of the House health reform bill, which will help i...ns and calls for swift passage of H.R. 3961 to sec...
(Date:11/8/2009)...ov. 8 March of Dimes ho...eon to recognize prominent individuals who are cel...ole models for March of Dimes commitment to improv...imes November Prematurity Awareness Month campaign...n the fight for preemies! ,, (Photo: http://w...
Breaking Medicine News(10 mins):Health News:College Invites Public to Explore Career Options in Health Care 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3
...) --,HearAtLast Holdings, Inc. is proud to announc...art Canada (NYSE: WMT ) to open its 16th hearing-...located at 255 Silver Linden,Dr. in Richmond Hill,... its option under a master licensing agreement wit...
...standard being adopted worldwide by, pharmaceutica... confirming digital iden...ms,(Nasdaq: ALDN ), an information security leade... hardware product,to be certified under the recent...
...Diverse Expertise, MIAMI, Dec. 9 Novis Pharmaceu...oducts to healthcare providers, is pleased,to anno...e President of,Human Resources. Ms. Lopez was most...ating from Florida International,University (FIU)....
...eruse of colorectal cancer screening procedures am...n the January 15, 2008 issue of CANCER, a peer-rev... that only 25 percent of Medicare patients receive... States. The American Cancer Society estimates tha...
... believe or disbelieve a statement is a powerful f...t the basis of these states in the brain is not ye...lief and uncertainty activate distinct regions of ... the Annals of Neurology ( http://www.interscience...
...sone improved pre, - and post-stem cell transplan... dexamethasone -, ATLANTA, Dec...M ) reported the presentation of results from an i...nd,dexamethasone (VcTD) to thalidomide and dexamet...
Other Medicine News:Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 2Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 3Health News:HearAtLast Continues Expansion Announcing Opening of New Clinic Location in Sam's Club in Richmond Hill, Ontario 4Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 2Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 3Health News:Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association 4Health News:Novis Pharmaceuticals Hires Lisa Lopez 2Health News:Many Medicare beneficiaries not receiving colorectal cancer screening 2Health News:Belief, disbelief and uncertainty activate distinct brain regions 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 2Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 3Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 4Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 5Health News:Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma 6
...o-Surgery provides clip appliers in 10mm and 5mm s...iers provide precise clip placement., ,The ALLPOR...e preloaded, single-trigger instruments are design... a 5mm trocar, through a 5mm reducer cap in a larg...
...P-HS assay utilizes turbidimetric immunoassay meth...uring over the range of 0.2-28.0 mg/dL. This assay...to most clinical chemistry analyzers. The Wako CRP...ecision, linearity, correlation, and sensitivity. ...
LabDAQ3 Laboratory Information System
...e for laboratories to work more efficiently has ne...e solutions. With the COBAS INTEGRA® 400 plus,...ies, robotic handling of reaction cuvettes and imp...broad menu and ease-of-use required for true workl...
Medicine Products: